U.S. Food and Drug Administration (FDA) Accepts for Priority Review Taiho Oncology’s New Drug Application for Futibatinib for Cholangiocarcinoma
School District To Host An Event Open To ‘Priority Families Only,’ Separating Attendees By Skin Color